Using human induced pluripotent stem cells (IPSCs), derived from skin cells of individuals, Neurxstem produces neural organoids that mimic CNS development at five weeks in development in vivo. These neural organoid mimic have all the major structures of the brain. This versatility in the laboratory helps investigators create models of human brain diseases and test new treatments.
Neural organoid description - complete from retina to spinal cord in 12 weeks
Leveraging proprietary technology in a fully equipped laboratory, Neurxstem can grow synthetic neural organoids from iPSC derived from skin cells. Neurxstem guarantees that these synthetic neural tissues mimic embryonic development within humans that is the developmental equivalent of ~5 weeks in utero, presenting an ideal drug screening platform.
• All human organoids are derived from iPSCs of fibroblast origin
• All major parts of the brain, retina, cortex, midbrain, hindbrain, and spinal cord are present by 12 weeks
• All major cell types including neurons, astrocytes, oligodendrocytes and microglia present by 12 weeks
Scalable in vitro - 96-well scalability currently
- Reproducibility: Results from two independent experiments show greater than 99% reproducibility in gene expression patterns. These data match well with the pattern of a human brain reference
- Replicability: Technical replicates from three independent iPSC lines show greater than 99% replicability of gene expression patterns
- Robustness: Three independent brain organoids, including those of male and female origin, show greater than 99% similarity in gene expression patterns
- Utility: Dysregulated gene expression patterns in models derived from patient skin cells recapitulate clinical phenotypes and pathology of Alzheimer’s disease and tuberous sclerosis
Some of our technology applications include:
Our neural organoids can be engineered with genetic predispositions for a wide range of diseases. This way, researchers can explore questions about brain disorders in greater depth — and find better ways to answer them. We demonstrate this utility through disease models of Alzheimer’s disease and tuberous sclerosis that we have created and analyzed using whole genome transcriptomics.
Drug discovery and testing
Our models can refine and accelerate the drug development process, decreasing cost and time to effective treatments.
Personalized diagnostics and prediction
Our neural organoids allow us to comprehensively assess how the brain expresses genes in response to environmental and genetic perturbations. Because they are derived from adult skin cells, we can begin to determine how genes and the environment give rise to an individual’s susceptibility to brain diseases and disorders.